Patents Assigned to MDIMUNE INC.
  • Publication number: 20230065508
    Abstract: Provided are a cell-extruding device including a membrane module, and a cell-extruding method using the same, wherein a suspension including cells is efficiently dispersed in the membrane module, thus preventing membrane clogging and increasing the usable area of the membrane, and thereby replacing the membrane and carrying out the process are easy, and production efficiency is increased.
    Type: Application
    Filed: September 18, 2020
    Publication date: March 2, 2023
    Applicant: MDIMUNE INC.
    Inventors: Dongwoo HAN, Shingyu BAE, Seungwook OH, Yunbeom SIM, Seonjoo LEE
  • Patent number: 10675244
    Abstract: The present invention relates to a microvesicle that is derived from nucleated mammalian cells, which are smaller than the nucleated cells. The microvesicles of the present invention can be used in the delivery of a therapeutic or diagnostic substance to specific tissues or cells, and more particularly, relates to microvesicles derived from monocytes, macrophages, dendritic cells, stem cells or the like, which can be used to deliver specific therapeutic or diagnostic substances for treating and/or diagnosing tissue associated with cancer, diseased blood vessels, inflammation, or the like.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: June 9, 2020
    Assignee: MDIMUNE INC.
    Inventors: Yong Song Gho, Yoon Keun Kim, Su Chul Jang, Oh Youn Kim, Dong-Sic Choi, Yae Jin Yoon
  • Publication number: 20190167587
    Abstract: Provided herein is a method for treating a pulmonary disease using mesenchymal stem cell-derived artificial nanosomes exhibiting a significantly excellent capability to regenerate alveoli compared to mesenchymal stem cells themselves and natural exosomes derived from human adipose-derived mesenchymal stem cells, wherein the mesenchymal stem cell-derived artificial nanosomes of the present disclosure may be collected through a simple production method using an extruder and an ultracentrifuge, instead of treating mesenchymal stem cells with a separate chemical substance and the potential side effects caused by stem cell therapeutic agents is low.
    Type: Application
    Filed: November 30, 2018
    Publication date: June 6, 2019
    Applicant: MDIMUNE INC.
    Inventors: Shin Gyu BAE, Yeon-Mok OH
  • Publication number: 20180296483
    Abstract: The present invention relates to a microvesicle that is derived from nucleated mammalian cells, which are smaller than the nucleated cells. The microvesicles of the present invention can be used in the delivery of a therapeutic or diagnostic substance to specific tissues or cells, and more particularly, relates to microvesicles derived from monocytes, macrophages, dendritic cells, stem cells or the like, which can be used to deliver specific therapeutic or diagnostic substances for treating and/or diagnosing tissue associated with cancer, diseased blood vessels, inflammation, or the like.
    Type: Application
    Filed: April 23, 2018
    Publication date: October 18, 2018
    Applicant: MDIMUNE INC.
    Inventors: Yong Song Gho, Yoon Keun Kim, Su Chul Jang, Oh Youn KIM, Dong-Sic CHOI, Yae Jin YOON